B.Riley Financial Reaffirms Their Buy Rating on Spectrum Pharmaceuticals (SPPI)

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Spectrum Pharmaceuticals (SPPIResearch Report) today and set a price target of $4.00. The company’s shares opened today at $1.50.

Mamtani covers the Healthcare sector, focusing on stocks such as Novavax, Altimmune, and Intercept Pharma. According to TipRanks, Mamtani has an average return of -22.6% and a 25.21% success rate on recommended stocks.

Spectrum Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $6.67, which is a 344.67% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.

See the top stocks recommended by analysts >>

SPPI market cap is currently $243.7M and has a P/E ratio of -1.80.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products. It operates through the following brands: FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, and EVOMELA. The company was founded in December 1987 and is headquartered in Henderson, NV.

Read More on SPPI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More